Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR ...

On Hump Day, investors piled into CRISPR Therapeutics (NASDAQ: CRSP) stock, sending its price more than 9% higher at the trading session's close. They were highly encouraged by the specialized ...

Why are CRISPR companies not OK? Will Robert F. Kennedy Jr. keep his promises if he's confirmed to lead the Department of ...

Beans are a key food at the dietary level, boasting high nutritional value and constituting the most directly consumed legume ...

While billions pour into pharmaceutical biotech, officials and experts warn there’s much less private investment in products more relevant to the military, like body armor materials, anti-corrosion ...

CRISPR Therapeutics (NASDAQ:CRSP) received an upgrade in its stock rating by analysts at TD Cowen, changing from Sell to Hold, while maintaining a price target of $35.00. The revision in the rating ...

CRISPR technology has radically transformed genetic research, and at the forefront of this transformation is CRISPR screening ...

I am Debjit, one of the therapeutic analysts here, and joining me from CRISPR Therapeutics is CEO, Samarth Kulkarni. Thank you so much, Sam. Yeah. Happy to do that. I think we’ve been around as ...

Scientists at UC San Francisco have pioneered a groundbreaking approach to fighting cancer using engineered fat cells. By ...

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader ...

Why are CRISPR companies not OK ... that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. We bring on our colleague Jason Mast to discuss the dramatic ...

The specialist in CRISPR-based gene editing – co-founded by Nobel Prize winner Jennifer Doudna – said it is focusing on NTLA-2002 for hereditary angioedema (HAE) and nexiguran ziclumeran (nex ...